3D Systems Corp banner

3D Systems Corp
NYSE:DDD

Watchlist Manager
3D Systems Corp Logo
3D Systems Corp
NYSE:DDD
Watchlist
Price: 2.11 USD 1.93% Market Closed
Market Cap: $308.2m

3D Systems Corp
Investor Relations

3D Systems Corp. is a holding company, which engages in the provision of comprehensive three-dimensional printing solutions. The company is headquartered in Rock Hill, South Carolina and currently employs 1,721 full-time employees. The company went IPO on 2011-03-26. The firm is principally engaged in providing three-dimensional (3D) printing and digital manufacturing solutions. Its products and solutions include 3D printers for plastics and metals, materials, software, maintenance and training services, and on demand solutions. Its solutions support applications in two key industry verticals: Healthcare, which includes dental and medical devices services; and Industrial, which includes aerospace and transportation. The firm offers a range of 3D printing technologies, including Stereolithography (SLA), Selective Laser Sintering (SLS), Direct Metal Printing (DMP), MultiJet Printing (MJP), ColorJet Printing and SLA based bioprinting. The company also offers 3D virtual reality simulators and simulator modules for medical applications. The company markets its products and services through subsidiaries in North America and South America, Europe and the Middle East, and the Asia Pacific region.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2025
Call Date
Mar 9, 2026
AI Summary
Q4 2025

Revenue: Q4 consolidated revenue was $106.3 million, up 16% sequentially and above the company's guidance of 8%–10% sequential growth.

Momentum: Management says Q4 strength was driven by new printer launches and materials demand with sequential improvement across Industrial and Healthcare segments.

Cost cuts: Completed roughly $55 million of annualized savings in 2025, helping adjusted EBITDA and operating expense performance.

Margins: Q4 non-GAAP gross margin was 31%; management expects gross margin improvement in Q1 2026.

Guidance: For Q1 2026 the company expects revenue of $91 million to $94 million and adjusted EBITDA of a loss of $5 million to a loss of $3 million.

Strategic growth areas: Aerospace & defense, personalized health services (PHS) and dental are highlighted as the primary drivers of future growth (A&D expected >20% growth in 2026).

Balance sheet: Ended Q4 with $97.1 million in total cash; materially restructured near-term debt so only $3.9 million remains maturing in 2026 and the remainder ($92 million) now matures in 2030.

Dental opportunity: Company projects >$400 million annual recurring materials opportunity globally from dentures over time, and began U.S. commercial shipments of its NextDent jetted denture platform in Q4.

Key Financials
Quarterly revenue (Q4 2025)
$106.3 million
Full year revenue (2025)
$387 million
Industrial Solutions revenue (Q4 2025)
$55.8 million
Healthcare Solutions revenue (Q4 2025)
$50.5 million
Non-GAAP gross margin (Q4 2025)
31%
Non-GAAP gross margin (Full year 2025)
34.3%
Non-GAAP operating expenses (Q4 2025)
$43 million
Non-GAAP operating expenses (Full year 2025)
$196 million
Annualized cost savings completed (2025)
$55 million
Adjusted EBITDA (Q4 2025)
negative $5.3 million
Adjusted EBITDA (Full year 2025)
negative $45.4 million
Non-GAAP loss per share (Full year 2025)
$0.37 loss per share
Cash and cash equivalents (Q4 2025)
$95.6 million (total cash $97.1 million including $1.5 million restricted)
Debt maturity profile (post-equitization)
$3.9 million maturing in 2026; $92 million scheduled to mature in 2030
Q1 2026 revenue guidance
$91 million to $94 million
Q1 2026 adjusted EBITDA guidance
loss of $5 million to loss of $3 million
Aerospace & Defense growth (2025) and outlook (2026)
16% growth in 2025; company expects >20% growth in 2026
Personalized planning cases (2025)
over 18,000 personalized planning cases in 2025 (total >400,000 patients cumulatively)
Customized patient implants (cumulative / 2025)
over 260,000 customized patient implants
Regulatory device clearances
raised total FDA and CE Mark device count to over 100
Dental materials market opportunity (company estimate)
over $400 million annual recurring revenue globally (materials only, long-term)
Earnings Call Recording
Other Earnings Calls

Management

Dr. Jeffrey Alan Graves Ph.D.
President, CEO & Director
No Bio Available
Mr. Reji Puthenveetil
Executive Vice President of Industrial Solutions, Additive Solutions & Chief Commercial Officer
No Bio Available
Mr. Jeffrey D. Creech
Executive VP, Principal Accounting Officer & CFO
No Bio Available
Ms. Phyllis B. Nordstrom
Executive VP, Chief People Officer & Chief Administrative Officer
No Bio Available
Dr. Charles W. Hull
Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus
No Bio Available
Dr. Joseph Zuiker
Executive Vice President of Engineering & Operations
No Bio Available
Mr. Michael McCloskey
Treasurer & VP of Investor Relations
No Bio Available
Mr. Andrew W.B. Wright J.D.
Senior VP of General Counsel & Corporate Secretary
No Bio Available
Mr. Harriss T. Currie
President - Regenerative Medicine
No Bio Available

Contacts

Address
SOUTH CAROLINA
Rock Hill
333 Three D Systems Cir
Contacts
+18033263900.0
www.3dsystems.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett